IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3358 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission

 


This article has been cited by
1Healthy volunteers in first-in-human oncology drug development for small molecules
Begoña de las Heras,Dalila Bouyoucef-Cherchalli,Lesley Reeve,Andreas Reichl,Debra Mandarino,Stephen Flach,Laura Vidal,Emilie M. J. van Brummelen,Neeltje Steeghs
British Journal of Clinical Pharmacology.2022;88(4)1773
[DOI]
2Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
Igor Radanovic,Naomi Klarenbeek,Robert Rissmann,Geert Jan Groeneveld,Emilie M. J. van Brummelen,Matthijs Moerland,Jacobus J. Bosch
Frontiers in Oncology.2022;12(4)1773
[DOI]
3Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
Shadreck Mwale
Frontiers in Oncology.2017;12(4)1
[DOI]
4Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
Shadreck Mwale
Frontiers in Oncology.2017;12(4)1
[DOI]
5A Clinical Review of Biosimilars Approved in Oncology
Dat Ngo,Jason Chen
Annals of Pharmacotherapy.2021;55(3)362
[DOI]
6First-in-Human, Healthy Volunteers Integrated Protocol of ETC -206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug
Vincenzo Teneggi,Veronica Novotny-Diermayr,Lay Hoon Lee,Maryam Yasin,Pauline Yeo,Kantharaj Ethirajulu,Sylvia Bong Hwa Gan,Stephanie E. Blanchard,Ranjani Nellore,Dhananjay N. Umrani,Roberto Gomeni,Darren Lim Wan Teck,Greg Li,Qing Shu Lu,Yang Cao,Alex Matter
Clinical and Translational Science.2020;13(1)57
[DOI]
7A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker
Christine Huynh,Andrea Henrich,Daniel S. Strasser,Marie-Laure Boof,Mohamed Al-Ibrahim,Henriette E. Meyer Zu Schwabedissen,Jasper Dingemanse,Mike Ufer
Clinical Pharmacology & Therapeutics.2021;109(6)1648
[DOI]
8Reviewing the role of healthy volunteer studies in drug development
Joyson J. Karakunnel,Nam Bui,Latha Palaniappan,Keith T. Schmidt,Kenneth W. Mahaffey,Briggs Morrison,William D. Figg,Shivaani Kummar
Journal of Translational Medicine.2018;16(1)1648
[DOI]
9Unveiling changes in the landscape of patient populations in cancer early drug development
Cinta Hierro,Analía Azaro,Guillem Argilés,Elena Elez,Patricia Gómez,Joan Carles,Jordi Rodon
Oncotarget.2017;8(8)14158
[DOI]
10Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
Mariam A. Ahmed,Chirag Patel,Nicole Drezner,Whitney Helms,Weiwei Tan,Daria Stypinski
Clinical and Translational Science.2020;13(1)31
[DOI]
11Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis
Yvonne Schuller,Christine Gispen-de Wied,Carla E. M. Hollak,Hubertus G. M. Leufkens,Violeta Stoyanova-Beninska
The Journal of Clinical Pharmacology.2019;59(2)229
[DOI]
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow